This BCC Research report presents a comprehensive look at disorders of the gastrointestinal system and their pharmacological treatment and diagnostic options. Forecast included from 2016 through 2021.
Use this report to: - Gain insight into disorders of the gastrointestinal system and their pharmacological treatment and diagnostic options. - Analyze diagnostic options and vaccines available for common gastrointestinal conditions. - Identify the gastrointestinal market landscape as well as important advancements.
Highlights - The global market for gastrointestinal disorder therapeutics and diagnostics reached $49.6 billion in 2015. This market is expected to grow from nearly $51.8 billion in 2016 to $63.8 billion in 2021 at a compound annual growth rate of 4.3% from 2016-2021. - The prescription therapies market is expected to grow from $18.6 billion in 2016 to nearly $22.1 billion in 2021 at a CAGR of 3.5% for the period 2016-2021. - The diagnostics market over the next five years will grow from $17.7 billion in 2016 to $23.5 billion in 2021 at a CAGR of 5.9% for the period 2016-2021.
STUDY GOALS AND OBJECTIVES The objective of this study is to present a comprehensive look at disorders of the gastrointestinal system and their pharmacological treatment and diagnostic options. There are two major categories of pharmacological treatment options available for gastrointestinal ailments: prescription drugs and over-the-counter (OTC) drugs.
This report will provide market analysis for the diagnostic options and vaccines available for common gastrointestinal conditions. Markets are further divided by type of therapeutic class of drugs available to treat some of the gastrointestinal conditions. The report provides an overview of the current and projected market with a five-year window for decision-makers interested in the gastrointestinal market arena.
REASONS FOR DOING THE STUDY This BCC Research study aims to increase the reader’s awareness of gastrointestinal disorders and to identify the gastrointestinal market landscape as well as important advancements. The study analyzes various therapeutic options currently on the market (inline) as well as potential products and classes of products that are likely to have a significant impact on the future (pipeline) for the prescription as well as the over-the-counter (OTC) gastrointestinal drug markets.
The gastrointestinal market is one of the key therapeutic areas most significantly affected by the generic erosion of block-busters. However, manufacturers of gastrointestinal drug products have stepped up the pace of research and development (R&D) as the engine driving growth in all markets, especially those involving new treatments for Crohn’s disease and irritable bowel syndrome (IBS).
INTENDED AUDIENCE The information and analyses presented in this report are important decision-making tools for managers involved in business development, marketing, market research, product development, mergers and acquisitions, licensing, business management, investment banking and deal creation, and for consultants to the pharmaceutical and biotechnology industry. The study provides a comprehensive analysis of the current and five-year estimated markets for gastrointestinal drugs and, in particular, the market potential of technologies under development in the gastrointestinal diagnostic arena.
SCOPE OF REPORT This report is designed to provide an in-depth look at the therapeutic and diagnostic options of various gastrointestinal disorders. The geographic scope of the report is global, with particular emphasis on the key markets such as the U.S. and the European Union Five (EU5). The estimated market data is also global in nature, with geographic segments such as the U.S., EU and Rest of the World (ROW). The report provides a brief overview of the gastrointestinal system, which provides an introduction to the disorders of the gastrointestinal system; cites risk factors, where applicable; presents current pharmaceutical treatments, market size and key market participants (both prescription and OTC); and presents potential treatments in R&D, potential market size and future market entrants.
As already mentioned, the market for gastrointestinal pharmaceuticals is divided into two general segments: prescription gastrointestinal pharmaceuticals and OTC gastrointestinal pharmaceuticals. Similarly, the market for gastrointestinal diagnostics, testing and vaccines is divided into three general segments: - Diagnostics and testing market. - Medical devices (endoscopy) - Vaccines.
The market is further broken down into the drugs to treat specific disorders within the gastrointestinal system, including the following: - Gastrointestinal tract disorders. - Gastrointestinal tract walls disorders. - Gastrointestinal motility disorders. - Gastrointestinal cancers.
Each sub-segment is covered in detail, describing the disorders and diseases, identifying currently available and potential products, and competitors.
METHODOLOGY AND INFORMATION SOURCES The information and analysis presented in this BCC Research report are based on extensive firsthand interviews with primary executives, product managers and clinical specialists in the gastrointestinal pharmaceutical arena. Background information was obtained from various government agencies, business and medical journals, trade magazines, and interviews with doctors and nurses involved in the treatment of gastrointestinal disorders.
Published literature served as the foundation for conducting interviews with various industry participants to obtain (and validate) expert opinions on current and future trends in the gastrointestinal pharmaceuticals industry. Secondary research along with focused interviews were the primary basis for the determination of market size and various market estimations. Interviews as well as findings from bio-medical literature were extensively used to confirm and/or adjust market size and market share estimates, as well as formulating market projections.
All market data pertain to the global market with an emphasis on the U.S. market at the manufacturer’s level. Data are expressed in current U.S. dollars. The base year was 2015 and forecast data are provided for 2021. Base year and forecast data are provided for each market segment and sub-segment. Market shares are provided for each market segment for the 2015 base year.
ANALYST’S CREDENTIALS Yogita Zutshi has 15 years of industry experience working in the areas of clinical operations, medical/regulatory writing and market research experience in the pharmaceutical domain. She has an MS in Clinical Research, an MS in Organic Chemistry, and a Bachelor’s degree in Education. She has also worked on research projects in Clinical Data Management (CDM), and has developed training modules for the clinical and pharmacovigilance areas. She has a high level of proficiency in customized market topline studies, secondary market research and competitive intelligence.
Our reports have been used by over 10K customers, including:
KEY INSIGHTS Gastro-esophageal reflux disease (GERD) is a chronic digestive disorder that occurs due to complications arising in the esophagus.The market is responsible for producing and distributing the drugs and devices required for its optimized cure and accurate diagnosis respectively. The global GERD drug and...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Traveler’s Diarrhea Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Traveler’s Diarrhea pipeline products. The Traveler’s Diarrhea pipeline guide presents complete overview of drugs currently...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Constipation Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Constipation pipeline products. The Constipation pipeline guide presents complete overview of drugs currently being developed for...
111 pages •
By Infiniti Research Limited
• Dec 2018
About this market The global antacids market sees an increasing trend of online transactions as the market is dominated by OTC drugs that require no prescription. It is easy for the consumption to shop online without requiring prior extensive product knowledge. The major reason for the increased popularity of e- commerce...
Traveler’s Diarrhea Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Traveler’s Diarrhea Global Clinical Trials Review, H2, 2018" provides an overview of Traveler’s Diarrhea clinical trials scenario.This report provides top line data relating to the clinical trials...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Diarrhea Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Diarrhea pipeline products. The Diarrhea pipeline guide presents complete overview of drugs currently being developed for Diarrhea. The...
Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene Like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 22.214.171.124) - Pipeline Review, H2 2018 Summary According to the recently published report ’Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.